Revenue: As of FY2025 Q4, the actual value is USD 146 M, missing the estimate of USD 148.24 M.<h3>Cash and Marketable Securities</h3>BridgeBio Pharma, Inc. estimates it had approximately $587.5 million in cash, cash equivalents, and marketable securities as of December 31, 2025.<h3>Net Product Revenue</h3>The company reported net product revenue of $146.0 million for the quarter ended December 31, 2025, and $362.4 million for the fiscal year ended December 31, 2025.<h3>Attruby Product Revenue</h3>Preliminary unaudited Q4 and full year 2025 net Attruby product revenue were $146.0 million and $362.4 million, respectively.<h3>Operational Metrics</h3><ul><li>Unique U.S. Patient Prescriptions for Attruby: 6,629 as of December 31, 2025.</li><li>Unique U.S. Prescribing HCPs for Attruby: 1,632 as of December 31, 2025.</li><li>Estimated Share of NBRx for Attruby: &gt;25% as of December 31, 2025.</li><li>Reduction in Cardiovascular Outcomes for ATTR-CM Patients: 42% reduction in cumulative frequency of cardiovascular-related hospitalization events at Month 30.</li><li>Reduction in Cardiovascular Mortality and Hospitalization Events: 50% reduction at Month 30.</li><li>Hazard Ratio for CVM or Recurrent CVH: 0.51 (95% CI: 0.43, 0.62), p-value &lt; 0.0001.</li></ul><h3>Unique Metrics</h3><ul><li>BBP-418: Positive Phase 3 interim result in LGMD2I/R9, with 1.8x increase in glycosylated αDG at 3 months and 82% decrease in CK at 12 months.</li><li>Encaleret: Positive Phase 3 result in ADH1, with 76% responder rate following 24 weeks of treatment.</li><li>Infigratinib: Last participant last visit completed for Phase 3 in achondroplasia, with topline expected in Q1 2026.</li><li>BBP-812: Ongoing pivotal trial in Canavan disease, with potential BLA filing in 2027 based on reductions in urine NAA and motor function improvements.</li></ul><h3>Outlook / Guidance</h3>BridgeBio Pharma, Inc. provided forward-looking statements regarding the commercial success of Attruby, clinical timelines, and potential market opportunities. The company anticipates interactions with regulatory authorities and expects to submit New Drug Applications with the FDA and similar submissions with foreign regulatory authorities. BridgeBio plans to advance a new TTR amyloid depleter antibody program into the clinic between 2027 and 2028. The company intends to submit a New Drug Application (NDA) for LGMD2I/R9 and encaleret in the first half of 2026, based on positive interim analysis and rapid diagnosis progress, respectively. BridgeBio is well-financed to hit potential milestones in 2026 and beyond.

Bridgebio Pharma | 8-K: FY2025 Q4 Revenue Misses Estimate at USD 146 M